- Home
- NCV vs TSHA Comparison
NCV vs TSHA Comparison
Compare NCV & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCV
- TSHA
- Stock Information
- Founded
- NCV 2003
- TSHA 2019
- Country
- NCV United States
- TSHA United States
- Employees
- NCV N/A
- TSHA N/A
- Industry
- NCV Finance Companies
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- NCV Finance
- TSHA Health Care
- Exchange
- NCV Nasdaq
- TSHA Nasdaq
- Market Cap
- NCV 299.1M
- TSHA 356.7M
- IPO Year
- NCV N/A
- TSHA 2020
- Fundamental
- Price
- NCV $13.19
- TSHA $1.64
- Analyst Decision
- NCV
- TSHA Strong Buy
- Analyst Count
- NCV 0
- TSHA 8
- Target Price
- NCV N/A
- TSHA $6.63
- AVG Volume (30 Days)
- NCV 405.1K
- TSHA 1.5M
- Earning Date
- NCV 01-01-0001
- TSHA 05-13-2025
- Dividend Yield
- NCV 12.48%
- TSHA N/A
- EPS Growth
- NCV N/A
- TSHA N/A
- EPS
- NCV N/A
- TSHA N/A
- Revenue
- NCV N/A
- TSHA $8,333,000.00
- Revenue This Year
- NCV N/A
- TSHA N/A
- Revenue Next Year
- NCV N/A
- TSHA N/A
- P/E Ratio
- NCV N/A
- TSHA N/A
- Revenue Growth
- NCV N/A
- TSHA N/A
- 52 Week Low
- NCV $2.84
- TSHA $1.19
- 52 Week High
- NCV $3.59
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- NCV 41.32
- TSHA 45.45
- Support Level
- NCV $12.70
- TSHA $1.69
- Resistance Level
- NCV $13.11
- TSHA $1.87
- Average True Range (ATR)
- NCV 0.21
- TSHA 0.11
- MACD
- NCV 0.03
- TSHA -0.00
- Stochastic Oscillator
- NCV 51.58
- TSHA 23.33
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.